

LUPUS NEPHRITIS: EPIDEMIOLOGICAL PROFILE AND TEMPORAL TREND OVER A PERIOD OF 19 YEARS



WCN24-AB-1643


Fernando Sales¹, Priscylla Vieira do Carmo¹, Nicolas William Gonçalves de Almeida¹, Mateus Henrique Toledo Lourenço¹, Natalia Maria da Silva Fernandes¹ ¹University Hospital of the Federal University of Juiz de Fora (HU-UFJF), Minas Gerais State, Brazil Interdisciplinary Center for Studies and Research in Nephrology of the UFJF (NIEPEN-UFJF)

Introduction

- → Lupus Nephritis (LN) is a complication that affects approximately 50% of cases of Systemic Lupus Erythematosus (SLE).
- → The objective of the study was to evaluate the profile of patients with LN in the Nephrology service of the University Hospital of the Federal University of Juiz de Fora.

Methods

- \rightarrow Retrospective cohort of patients with LN from 2003 to 2022.
- → Sociodemographic, clinical and laboratory variables were evaluated at admission and at the end of the study.
- \rightarrow Outcomes: estimated glomerular filtration rate (eGFR) and proteinuria.



Comorbidities

Systemic Arterial	
Hypertension	81.9%
Dyslipidemia	48.2%
Psychiatric illnesses	47.0%
.,	
Bone Diseases	18.1%
Diabetes Mellitus	14.5%
Thyroidopathy	12.0%
Cardiovascular diseases	9.6%
Antiphospholipid syndrome	9.6%
Nephrolithiasis	8.4%
Diabetes Mellitus Thyroidopathy Cardiovascular diseases Antiphospholipid syndrome	47.0% 18.1% 14.5% 12.0% 9.6% 9.6%

1 Kidney

biopsy

31%

Immunosuppressants

Corticosteroids	100%
Hydroxychloroquine	94%
Azathioprine	66.3%
Mycophenolate	50.6%
Intravenous therapi	
	163
Corticosteroids	75.9%
Cyclophosphamide	61.4%
Belimumab	9.6%
Rituximab	2.4%

Rapidly

progressive

GN

≥2 Kidney

biopsies


23%

29%

Crescents

on initial

biopsy



Conclusions

- \rightarrow Predominance of young, female patients, class IV or IV/V, with improvement in eGFR and proteinuria level.
- → Knowledge of the epidemiological profile of lupus nephritis is essential for guiding managers of public systems to optimize health care and better renal outcomes.

nataliafernandes02@gmail.com fernansales@gmail.com